Concepedia

N. Hertel

NH

Statistics

Publications

11

Citations

289

H-Index

10

Active since

2008

Affiliations

Grünenthal Group (Germany)(Current)

Bristol-Myers Squibb (United Kingdom)

University Hospital Schleswig-Holstein

Bristol-Myers Squibb (United States)

Bristol-Myers Squibb (France)

N. Hertel is an author at Grünenthal Group (Germany) specializing in pharmacoeconomics, cost-effectiveness analysis, and pharmacy.

Publications per year

2008–2021

11

Publications

11

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis

N. Hertel, Kotchie, Yevgeniy Samyshkin et al. · International Journal of COPD · 2012 · 46 citations · Full text

, , +17

<p>Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe</p>

Katharina Verleger, John R. Penrod, Melinda Manley Daumont et al. · ClinicoEconomics and Outcomes Research · 2020 · 36 citations · Full text

, , +17

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England

Yang Meng, N. Hertel, J. Ellis et al. · The European Journal of Health Economics · 2018 · 31 citations · Full text

, , +17

Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine

R. Ikenberg, N. Hertel, Andrew Moore et al. · Journal of Medical Economics · 2012 · 28 citations · Full text

, , +15

Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways

Hanno M. Witte, Axel Künstner, N. Hertel et al. · Blood Advances · 2021 · 28 citations · Full text

, , +17

1–5 of 11